BamSEC and AlphaSense Join Forces
Learn More

Immunome Inc. – Material Contracts

Formerly NASDAQ: IMNM
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 5 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 3 to License Agreement Background
12/34/56
EX-10.3
from 10-Q 6 pages Third Amendment to Lease
12/34/56
EX-10.2
from 10-Q 8 pages First Amendment to Lease
12/34/56
EX-10.1
from 10-Q 40 pages Immunome, Inc 2024 Inducement Plan Effective as Of: October 3, 2024 Amended by the Compensation Committee as Of: May 8, 2025
12/34/56
EX-10.28
from 10-K 77 pages Alloy Innovation Center Lease
12/34/56
EX-10.27
from 10-K 9 pages Second Amendment to Lease
12/34/56
EX-10.24
from 10-K 2 pages ​ Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.11
from 10-K 37 pages Immunome, Inc 2024 Inducement Plan Effective as Of: October 3, 2024
12/34/56
EX-10.7
from 10-K 18 pages Immunome, Inc. Executive Stock Option Grant Notice
12/34/56
EX-10.1
from 8-K 2 pages January 20, 2025 Max Rosett Mrosett@immunome.com Re: Relocation Package Dear Max
12/34/56
EX-10.2
from 10-Q 4 pages Background
12/34/56
EX-10.1
from 10-Q 11 pages May 24, 2024 Phil Tsai Re:immunome, Inc. Employment Offer Dear Phil
12/34/56
EX-10.38
from 10-K 6 pages ​ April 26, 2021 ​ Robert Lapetina 708 Julian Drive Collegeville, Pa 19426 ​ Dear Bob, ​ on Behalf of Immunome, Inc. (The “Company”), I Am Pleased to Make This Conditional Offer of Employment to You as Our Controller. the Purpose of This Letter Agreement Is to Set Forth the Terms of the Offer and Your Employment Should You Accept the Offer. ​ 1. Position: Duties: ​
12/34/56
EX-10.37
from 10-K 65 pages Asset Purchase Agreement ​ by and Between ​ Atreca, Inc. ​ and ​ Immunome, Inc. ​ Dated as of December 22, 2023 ​
12/34/56
EX-10.34
from 10-K 10 pages October 3, 2023 by Hand and Email Purnanand Sarma Sarmap97@gmail.com Re:separation Agreement Dear Sarma
12/34/56
EX-10.33
from 10-K 9 pages Immunome, Inc. Consulting Agreement
12/34/56
EX-10.32
from 10-K 9 pages October 2, 2023 by Hand and Email Dennis Giesing Dhgiesing@gmail.com Re:separation Agreement Dear Dennis
12/34/56
EX-10.30
from 10-K 56 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Zentalis Pharmaceuticals, Inc. and Immunome, Inc. License Agreement January 5, 2024 ​
12/34/56
EX-10.23
from 10-K 11 pages February 7, 2024 Kinney Horn Re:immunome, Inc. Employment Offer Dear Kinney
12/34/56
EX-10.22
from 10-K 11 pages November 30, 2023 Philip Roberts Re:immunome, Inc. Employment Offer Dear Phil
12/34/56